
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ:GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.
But, the upshot is that the stock is one of the cheapest in the large-cap biotech and pharma sector, writes Wall Street Journal.